since IPO. I think comms are the usual but transparent. Keeping an eye on cash runway and delivery of milestones to see if they deliver - so far so good.
510k applications don’t have a good track record for ASX bios hopefully this is about to change. AYA is another with FDA decision due this month.
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark, page-24
Add COV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $31.82M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $23.50K | 62.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1360 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 10750 | 1 |
View Market Depth
| Last trade - 11.34am 11/07/2024 (20 minute delay) ? |
| COV (ASX) Chart |